Chronic neurological disorder of the brain is the main reason for the disease epilepsy, which affects people of almost all ages. According to World Health Organization estimates, particularly in developing regions of the world nearly 80% of people suffer from different forms of epilepsy. The majority of epileptic seizures are controlled by the use of antiepileptic drugs, which are often associated with related side effects such as blurry vision, fatigue, sleepiness, and stomach upset. Lennox–Gastaut syndrome (LGS) is childhood-onset epilepsy with multiple different types of seizures that impair intellectual development. To treat LGS, Novartis developed an antiepileptic drug known as rufinamide that contains a 1,2,3-triazole ring, and it is manufactured by Eisai under the brand name of Banzel or Inovelon. This review provides a brief background on LGS and summarizes the literature reports on different synthetic routes for rufinamide, which was approved by the U.S. Food and Drug Administration in November 2008.

中文翻译：

---

合成抗癫痫药鲁芬酰胺的合成进展简述

大脑的慢性神经系统疾病是癫痫病的主要原因，这种疾病影响几乎所有年龄段的人。根据世界卫生组织的估计，特别是在世界发展中地区，近80％的人患有不同形式的癫痫病。大多数癫痫发作是通过使用抗癫痫药控制的，抗癫痫药通常与相关的副作用有关，例如视力模糊，疲劳，嗜睡和胃部不适。Lennox–Gastaut综合征（LGS）是儿童发作的癫痫病，伴有多种不同类型的癫痫发作，损害了智力发育。为了治疗LGS，诺华开发了一种抗癫痫药，称为rufinamide，它含有1,2,3-三唑环，由Eisai以Banzel或Inovelon的商标生产。